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ABSTRACT
The primary goal of my thesis research was to characterize the basis for
the hypersensitive response of glycogen phosphorylase to catecholamine
stimulation in primary culture diabetic cardiomyocytes. Toward this goal , I have
investigated several key regulatory sites in this signaling pathway which could
promote the hypersensitive activation of phosphorylase. Specifically, I
investigated (1) which adrenergic receptors are involved in mediating the
hypersensitive response of glycogen phosphorylase to epinephrine stimulation;
) whether the presence of fatty acid metabolites affects phosphorylase
activation; (.3) whether the hypersensitive response of phosphorylase results from
altered signal transduction through the -adrenergic receptor system or from a
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post-receptor defect; and (.4) the potential role for phosphorylase kinase 
mediating the hypersensitive response of phosphorylase to catecholamine
stimulation.
The basis for adrenergic receptor mediation of the catecholamine- induced
activation of glycogen phosphorylase was investigated in adult rat
cardiomyocytes isolated from normal and alloxan-diabetic animals. Cells derived
from diabetic animals exhibited a hypersensitive response to epinephrine
stimulation which was apparent 3 hours after cell isolation and was further
enhanced upon maintenance of the myocytes in culture for 24 hours. Normal
cells initially lacked the hypersensitive response to epinephrine stimulation
although upon maintenance of these cells in culture for 24 hours, the
hypersensitive response was acquired in vitro. To assess alpha- and beta-
adrenergic mediation of the response, normal and diabetic cardiomyocytes were
incubated with propranolol , a ~-receptor antagonist, prior to direct a1 receptor
stimulation with phenylephrine. Both normal and diabetic myocytes failed to
undergo activation of phosphorylase in 3 or 24 hour cell cultures. In addition , the
effects of epinephrine on phosphorylase activation were completely inhibited by
propranolol whereas prazosin , an a-receptor antagonist, was unsuccessful. This
data suggests that the hypersensitive response of glycogen phosphorylase in
normal and diabetic cardiomyocytes is solely mediated through ~-adrenergic
receptor activation.
Since the accumulation of various fatty acid metabolites can affect certain
enzymes and signal transduction pathways within the cell , the potential effect of
various fatty acid metabolites on phosphorylase activation was investigated. To
determine the potential effects of fatty acid metabolites on phosphorylase
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activation in cultured cardiomyocytes, normal and alloxan-diabetic cells were
incubated with either carnitine or palmitoylcarnitine prior to stimulation with
epinephrine. Pretreatment of cardiomyocytes with or without carnitine or
palmitoylcarnitine for 3 or 24 hours before epinephrine stimulation failed to alter
phosphorylase activation. The addition of exogenous carnitine in the absence
and presence of insulin was also unsuccessful in attenuating the hypersensitive
phosphorylase activation response in 3 and 24 hour, normal and alloxan-diabetic
derived cardiomyocytes. To determine if carnitine palmitoyltransferase 1 (CPT-
activity was responsible for the hypersensitive response of phosphorylase in the
diabetic myocytes, both normal and diabetic myocytes were maintained for 3 and
24 hours in the absence and presence of etomoxir, a CPT- inhibitor.
Subsequent activation of phosphorylase by epinephrine in normal and diabetic
myocytes was unaltered in the presence of etomoxir. Collectively, these data fail
to support a critical role for fatty acid metabolite involvement in the hypersensitive
activation of glycogen phosphorylase in acute, alloxan-diabetic cardiomyocytes.
To assess potential G-protein involvement in the response, normal and
diabetic-derived myocytes were incubated with either cholera or pertussis toxin
prior to hormonal stimulation. Pretreatment of cardiomyocytes with cholera toxin
resulted in a potentiated response to epinephrine stimulation whereas pertussis
toxin did not affect the activation of this signaling pathway. To determine if the
enhanced response of phosphorylase activation resulted from an alteration in
adenylyl cyclase activation , the cells were challenged with forskolin. After 3 hours
in primary culture, diabetic cardiomyocytes exhibited a hypersensitive response
to forskolin stimulation relative to normal cells. However, after 24 hours in culture,
both normal and diabetic myocytes responded identically to forskolin challenge.
The present data suggest that a cholera toxin sensitive G-protein mediates the
hypersensitive response of glycogen phosphorylase to catecholamine stimulation
in diabetic cardiomyocytes. This response, which is present in alloxan-diabetic
cells, and is induced in vitro in normal cardiomyocytes, is primarily due to a
defect at a post-receptor site.
To assess the role of phosphorylase kinase in the hypersensitive
activation of glycogen phosphorylase in the diabetic heart, phosphorylase kinase
activity was measured initially in perfused hearts (to optimize the assay
parameters) and subsequently in primary culture cardiomyocytes. Results from
these experiments demonstrate that the present method for measuring
phosphorylase kinase activity is a reliable indicator of the enzyme s activity in the
heart, although the assay conditions must be further optimized before this system
can be applied to the measurement of phosphorylase kinase activity in primary
cultured cardiomyocytes.
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CHAPTER I
Introduction
Phosphorylase (a- 1 , gulcan: orthophosphate glycosyl transferase, E.
2.4. ), catalyzes the initial step in the intracellular degradation of glycogen by
liberating glucose- phosphate from the glycogen particle (Figure 1) (46).
Phosphorylase exists in the cell in two forms: phosphorylase Q, which is
essentially nonactivated in vivo and phosphorylase a, which is physiologically
active (30). The active enzyme is a dimer composed of two identical 97-kdal
subunits (46). Phosphorylase, as with other enzymes involved in glycogen
metabolism, is regulated by both allosteric effectors and reversible serine
phosphorylation , but of the two, phosphorylation is the dominant regulatory
mechanism (9,47).
Phosphorylase 12, the dephosphorylated form of the enzyme, is active only
in the presence of high concentrations of AMP , which acts allosterically (46).
AMP and, to a lesser extent , IMP , bind to the nucleoside binding site of the
enzyme to alter its conformation and enhance its activity (9,30). A TP acts as 
negative allosteric effector by competing with AMP, whereas, glucose-
phosphate also inhibits phosphorylase .b by binding at the same site (46). In
contrast, phosphorylase a is fully active regardless of the levels of AMP , ATP
and glucose- phosphate (30).
Phosphorylase .b may be converted to phosphorylase a. upon
phosphorylation (69, 82). In response to nervous or hormonal stimulation
phosphorylase .b is phosphorylated at a single position in the amino-terminus,
serine- 14, by phosphorylase kinase as part of the cAMP cascade (47, 82).
Activation by phosphorylation is reversed by the reciprocal action of
phosphorylase phosphatase, a type 1 protein phosphatase (9, 62). The rate of
cellular glycogenolysis is directly dependent on the balance of opposing
enzymatic activities which are responsible for maintaining phosphorylase in the a
form.
The role of catecholamines in cardiac function has been well documented.
In 1965, it was reported that epinephrine caused a rapid rise in cAMP production,
enhanced both chronotropic and inotropic response and promoted the conversion
of phosphorylase from the .b to the a form in the perfused rat heart (74). With
time, the cascading sequence of events by which epinephrine induced the
activation of phosphorylase was described (Figure 2).
Activation of glycogen phosphorylase by epinephrine requires the coupling
of cell surface receptors to the adenylyl cyclase system by receptor- linked G-
proteins (4 15). For hormones which utilize cAMP as an intracellular messenger,
two groups of G-proteins, Gs and Gi mediate the receptor-dependent stimulation
or inhibition of adenylyl cyclase activity respectively (34,81). Stimulation of
adenylyl cyclase results in increased intracellular cAMP levels which then
activates cAMP-dependent protein kinase (A-kinase) (73). A-kinase then
. phosphorylates and activates phosphorylase kinase which catalyzes the
conversion of phosphorylase from the .b to the a form (22 83).
In diabetic or severely insulin deficient rats, cardiac glycogen
phosphorylase activation , in response to epinephrine challenge is altered. When
hearts from alloxan-diabetic rats were perfused for periods up to 10 minutes with
epinephrine, activation of phosphorylase in diabetic hearts was significantly
greater at every time point and at every epinephrine concentration than the
normal response to the hormone (64). The diabetic response to epinephrine was
termed "hypersensitive" (63,64). In the diabetic heart, protein kinase activity and
cAMP levels were not shown to be significantly different than the normal
response to epinephrine stimulation (1 64). In these hearts, phosphorylase
phosphatase activity was found not to be altered by diabetes or epinephrine
challenge whereas, phosphorylase kinase activation in the diabetic hearts was
double the normal response to the hormone (64). Subsequent studies utilizing
isolated perfused hearts from alloxan-diabetic animals showed that upon
perfusion of the hearts with sub physiological calcium concentrations,
approximately one-third of the normal perfusate calcium concentration , partially
reversed the diabetes-related hypersensitivity of phosphorylase activation by
epinephrine (63). What these data collectively suggested is that the
hypersensitivity of phosphorylase activation in the diabetic was due to enhanced
sensitivity of phosphorylase kinase activation by a factor or factors beyond the
protein kinase level , possibly due to an increase in intracellular free calcium
concentrations.
The majority of these types of studies were carried out using isolated
perfused hearts which limit the information which can be obtained. The perfused
heart preparation is limited as to the length of the perfusion time due to metabolic
and hemodynamic failure (89). Upon establishment of a primary cell culture
system, further studies addressing the response of phosphorylase in the diabetic
heart could be undertaken (89). Myocytes isolated from hearts of adult rats offer
a number of distinct advantages over other heart preparations. Since this
preparation results in a high yield of a single cell type, isolated myocytes are
ideal preparations for biochemical and in vitro pharmacological studies (28,89).
Primary culture techniques using laminin coated culture dishes significantly
enhanced the plating efficiency of the preparation and enabled the
cardiomyocytes to be maintained under tightly controlled conditions (11 89).
Since primary culture cells are viable for several days or even weeks, this system
lends itself to the study of the mechanisms involved in the diabetes-related
hypersensitivity of phosphorylase (89). The initial studies using this system
showed that cells derived from alloxan-diabetic hearts exhibited a hypersensitive
phosphorylase activation response after placement into primary culture which
was similar to that demonstrated with the perfused heart preparation (89). Upon
maintenance of normal and alloxan-diabetic derived cardiomyocytes in culture for
24 hours, it was shown that diabetic myocytes were further sensitized to
stimulation with epinephrine and the effect was induced in vitro to the same
extent in normal cardiomyocytes (11). The physiological basis for the
hypersensitive response in the diabetic and the in vitro acquisition of the
response in the normal myocytes remains unknown.
The focus of my dissertation has been geared toward characterizing the
molecular basis for the hypersensitive response of glycogen phosphorylase to
epinephrine stimulation in primary culture, alloxan-diabetic cardiomyocytes.
Toward this goal , I have addressed the following questions:
1. Which adrenergic receptors are involved in mediating the hypersensitive
response of glycogen phosphorylase to epinephrine stimulation?
Does the accumulation of fatty acid metabolites affect phosphorylase
activation in acute, diabetic-derived cardiomyocytes?
3. Does the hypersensitive response of glycogen phosphorylase activation to
catecholamine stimulation result from altered signal transduction through the ~-
adrenergic receptor system or from a post-receptor defect?
4. Is the hypersensitive response of phosphorylase due to a defect at the level of
phosphorylase kinase?
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CHAPTER II
Materials and Methods
A. Reagents.
(14C)glucose- phosphate, (35S)methionine protein labeling mix and 
(y-
32p)A TP were purchased from New England Nuclear. Epinephrine, propranolol
prazosin, carnitine, palmitoylcarnitine, forskolin , cholera and pertussis toxins,
phosphorylase kinase and crystallne bovine serum albumin were purchased
from Sigma. Phosphorylase 12 was purchased from Sigma, Boehringer Mannheim
and was generously provided by Dr. James Dobson. Etomoxir was generously
provided by Dr. H. O. Wolf of Byk Gulden Pharmazeutika (Konstanz, Germany).
Laminin was obtained from Collaborative Research and Boehringer Mannheim.
Collagenase and hyaluronidase were purchased from Worthington. All other
chemicals were reagent grade products obtained from commercial sources.
B. Animals.
Male, albino, Sprague-Dawley CD outbred rats weighing between 175 and
250 grams were used for all experiments. Diabetes was induced by injection of
alloxan (60 mg/kg) into the tail veins of animals which had been previously fasted
overnight. Animals were used 3 to 5 days after alloxan injection and diabetes was
diagnosed the day of perfusion using Ames Keto-Diastix (positive maximum
glucose and ketone bodies in urine).
C. Preparation of Cardiomyocytes.
Cardiomyocytes were prepared according to the method described by
Wolleben et al. (89). Briefly, hearts were perfused through the aorta in a
retrograde fashion with Krebs-Henseleit bicarbonate buffer containing 5 
glucose and 2.5 mM calcium. All hearts were equilibrated in this manner and then
briefly switched to a second reservoir containing the same buffer without calcium
to stop contraction of the hearts. The hearts were then perfused with Krebs-
Henseleit buffer containing 50 IlM calcium , 0. 1 % bovine serum albumin (BSA),
312 U/ml hyaluronidase, and 0. 1 % collagenase. After this final perfusion , the
ventricles were trimmed free of atria and incubated in Krebs-Henseleit buffer
containing 50 IlM calcium , 0.2% BSA , 312 U/ml hyaluronidase and 0. 1 %
collagenase in a 37 C water bath with gentle shaking. At 10 minute intervals, the
enzyme solution was aspirated and replaced, and the incubation was continued
until the tissue became flaccid. The ventricular tissue was dissociated by
vigorous shaking for 10 minutes at 37 C. The resulting cell suspensions were
filtered through nylon mesh and washed with Krebs-Henseleit buffer containing
100 IlM calcium and 0.5% BSA. The cells were allowed to pellet by gravity and
were washed twice in the same buffer prior to resuspension in minimal essential
media (MEM) containing Earles ' salts, 26 mM sodium bicarbonate, 5 
creatine, 20 mM Hepes, 100 U/ml Penicillin G , 100 1l9/ml streptomycin and 1.
mM calcium (supplemented MEM). The myocytes were then seeded onto 60 mm
laminin coated (20 1l9/ml), Falcon plastic culture dishes containing 2 ml of the
same media. The cells were maintained in a 95% air:5% C02 incubator for the
duration of the experiment. All cells were allowed to equilibrate for 2 hours prior
to washing and refeeding with the same media containing 0.2 mM palmitate and
24% albumin.
For the adrenergic receptor studies, freshly isolated cells (2 hours in
culture), were equilibrated for one additional hour in the absence or presence of
adrenergic antagonists prior to hormonal challenge. Cells were maintained in
culture for 24 hours in supplemented MEM containing 0.2 mM palmitate and
24% albumin in the absence of antagonists prior to refeeding with the same
media, with or without antagonists. As with 3 hour cells, 24 hour cells were
allowed to equilibrate for 1 hour after refeeding prior to hormonal challenge.
For the fatty acid metabolite studies, cells were maintained in primary
culture for 2 hours prior to washing and refeeding with medium containing 0.24%
albumin (without palmitate) and the appropriate concentration of
palmitoylcarnitine, carnitine and/or insulin for 1 or 22 additional hours prior to
epinephrine challenge. For the studies with etomoxir, cardiomyocytes were
maintained in primary culture for 2 hours prior to washing and refeeding with
medium containing 0.24% albumin (without palmitate) and the appropriate
concentration of etomoxir for the appropriate time prior to stimulation with
epinephrine.
For the G-protein studies, cells were maintained in primary culture for 2
hours and were equilbrated in the absence or presence of 25 J.g/ml cholera toxin
or 1 J.g/ml pertussis toxin for 1 hour prior to stimulation with epinephrine. Three
hour cells for the forskolin dose response studies were equilibrated for 1
additional hour in supplemented MEM containing 0.2 mM palmitate and 0. 24%
BSA and 24 hour cells were maintained in culture overnight in the same medium.
Forskolin stocks (10 mM) were prepared fresh in dimethyl sulfoxide (DMSO) and
serial dilutions were made using 0.9% sterile saline.
For cells isolated for the phosphorylase kinase studies, the cells were
maintained in primary culture for 2 hours prior to washing and refeeding with
medium containing 0.2 mM palmitate and 0.24% albumin. The cardiomyocytes
were maintained in primary culture for one additional hour (3 hours total) or
overnight (24 hours total) prior to epinephrine challenge. After agonist exposure
for the appropriate time, all myocytes were washed with buffer containing 50 mM
tris (pH 7.8), and 5 mM EDT A prior to freezing by floating the culture dish on
liquid nitrogen and storing at -
D. Phosphorylase Assay.
Frozen cells were thawed on ice and the cells scraped from the dish using
a rubber policeman. Myocytes were washed with ice cold homogenization buffer
containing 50 mM tris (pH 7.8), 5 mM EDT A, 50 mM sodium fluoride and 1 mg/ml
oyster glycogen. The resulting suspensions were sonicated for 30 seconds prior
to microcentrifugation for 5 minutes. Cell supernatants were assayed for
phosphorylase activity in the absence and presence of AMP , based on the
method of Gilboe et al. which measures (14C)glucose- phosphate incorporation
into glycogen (32). Phosphorylase activity is expressed as the ratio of AMP
independent (phosphorylase a activity) to total activity assayed in the presence of
AMP (phosphorylase a + .t activity) to determine " % phosphorylase a:.
Glycogen phosphorylase activity may be assayed in either the direction of
glycogen degradation or glycogen synthesis. In the forward reaction, toward
glycogen degradation , phosphorylase activity is measured based on glucose-
phosphate release from glycogen , in the presence of inorganic phosphate
(12 38). Although this assay method is more physiologically relevant for these
studies, there are several drawbacks (i. e. low sensitivity and high background)
which render this protocol inappropriate for use with primary culture
cardiomyocytes (32 38). The preferred method for monitoring changes in
phosphorylase activity was to measure the reverse reaction , toward glycogen
synthesis at decreased pH. Under slightly more acidic conditions (pH 6. 1), the
reaction equilibrium favors phosphorylase activity in the direction of glycogen
synthesis (32 33). In addition , phosphoglucomutase, the enzyme which catalyzes
the conversion of glucose- phosphate to glucose- phosphate and is present in
cell extracts, is inhibited at this pH to yield more accurate results (33). Since the
reverse reaction toward glycogen synthesis monitors (14C)glucose- phosphate
incorporation into glycogen , the specific activity of glucose- phosphate may be
increased to enhance the assay s sensitivity and to optimize the system for use in
microassays or with various heart preparations (32).
E. Metabolic Cell Radiolabeling.
Before labeling, normal and diabetic isolated cardiomyocytes were
incubated for 2 hours prior to washing and refeeding. The medium was replaced
with fresh supplemented MEM containing 0.2 mM palmitate, 0.24% albumin and
50 IlCi/ml (35S)methionine protein labeling mix, with or without cycloheximide,
and the cells were incubated for an additional 2 hours. After labeling, the cells
were rinsed twice with ice cold buffer containing 50 mM tris (pH 7.8) and 5 mM
EDTA and frozen by floating the plate on liquid nitrogen. Dishes were stored at
C before analysis.
F. Total Protein Synthesis Determination.
Using a rubber policeman , frozen cardiomyocytes were scraped from
culture dishes in lysis buffer containing 50 mM tris (pH 7.4), 5 mM EDTA, 100
mM sodium fluoride, 1 % NP-40, 1 mM PMSF, 1 mM benzamidine, 1 Jlg/ml
leupeptin and 1 Jlg/ml pepstatin. The suspensions were homogenized for 12
seconds with a Polytron homogenizer and were centrifuged at 10,000 x g for 15
minutes. The supernatants were assayed for protein content. Aliquots containing
10 Jlg of sample protein were precipitated onto a nitrocellulose filter (Schleicher
and Schuell) with ice cold 10% trichloroacetic acid (TCA) in a BRL dot blot
apparatus. Each sample was washed twice with an additional 250 JlI of 10% TCA
and individual spots were cut and counted by liquid scintillation methods using
Optifluor to determine (35S)methionine incorporated into protein.
G. Phosphorylase Kinase Assay.
Phosphorylase kinase activity was assayed based on the method 
McCullough and Walsh (58) as modified in (2) which measures the incorporation
of 32p from (y_32p)ATP into phosphorylase 12. Briefly, rat hearts were perfused
with glucose-free, Krebs-Henseleit buffer containing 2.5 mM calcium for 30
minutes to deplete the endogenous glycogen stores. Control hearts (- Epi) were
freeze clamped using Wollenberger tongs pre-cooled in liquid nitrogen while the
remaining hearts were perfused for an additional 5 minutes with the same buffer
containing 10 JlM epinephrine (+ Epi) before freezing.
Frozen hearts were individually powdered using a mortar and pestle and
150 mg of heart powder was suspended in approximately 2 volumes of
homogenization buffer containing 30 mM tris (pH 7.5), 30 mM potassium
chloride , 5 mM EDT A , 100 mM sodium fluoride, 1 mM PM SF , 1 mM benzamidine
and 1 Jlg/mlleupeptin and pepstatin. The heart extracts were then sonicated for
60 seconds and microcentrifuged. The resulting supernatants were diluted with
an equal volume of dilution buffer which contained 30 mM glycerophosphate (pH
8), 5 mM EDT A, 100 mM sodium fluoride and 45 mM 2-mercaptoethanol. The
reaction was initiated by adding 10 JlI of diluted extract or buffer (OOC) to 50 JlI of
reaction mixture (30 C) which consisted of 50 mM tris (pH 6.8), 53 
glycerophosphate, 12 mM magnesium acetate, 20 JlM calcium chloride, 12 mg/ml
glycogen , 2 Jlg cAMP-dependent protein kinase inhibitor (PKI), 1 mM (y_32p)ATP
(220 cpm/pmol), 18 mM 2-mercaptoethanol , with or without 6 mg/ml
phosphorylase .b. The reaction mixture was routinely incubated at 30 C for 2
minutes prior to the addition of sample to avoid cold inactivation of phosphorylase
.b (33,72). The reaction was terminated after 10 minutes by spotting 40 JlI of the
reaction mixture onto Whatman filter papers which were immediately immersed
into an ice cold wash containing 10% trichloroacetic acid (TCA) and 50 
potassium pyrophosphate. The filters were washed three more times with 10%
TCA , 50 mM potassium pyrophosphate followed by one wash each in 50%
ethanol and acetone. The dried filters were counted by liquid scintillation methods
with Optifluor.
Isolated myocytes were assayed for phosphorylase kinase by scraping the
cells from the plates using a rubber policeman and homogenization buffer. Cell
suspensions were sonicated and microcentrifuged. 10 JlI of the cell supernatant
(OOC), without further dilution, was added to 50 JlI reaction mixture (30 C) to
initiate the reaction. The assay incubation time was extended to 60 minutes and
the reaction was terminated as described above.
H. Protein Content Determination.
In conjunction with the phosphorylase a assays, cell supernatants were
routinely assayed for protein content using the Bio Rad Protein Assay. When
(35S)methionine labeled cells were harvested, detergent-containing extracts were
assayed for protein content by the BCA Protein Assay.
I. Data Computation and Expression.
Data are expressed as means plus one standard error on either side of the
mean. EC50 values were calculated by non regression analysis using Graph Pad
software. Statistical significance was determined by Student's t-est.
CHAPTE R II
Characterization of Adrenergic Receptor Involvement in Glycogen
Phosphorylase Activation
A. Introduction.
Glycogen phosphorylase plays a key role in the control of energy supply in
the heart by regulating the rate of glycogen degradation (glycogenolysis).
Phosphorylase , as with other enzymes involved in glycogen metabolism , is
regulated on a minute to minute basis by various circulating hormones which
stimulate or depress its activity based on their abilty to promote phosphorylation
or dephosphorylation the enzyme (13, 19, 42). The phosphorylated form of the
enzyme, phosphorylase a, is physiologically active while the dephosphorylated
form, phosphorylase 
.Q, is nonactivated in vivo. The rate of glycogenolysis is
therefore dependent on the amount of phosphorylase which is present in the a
form.
Epinephrine, a circulating cardiac catecholamine, has been shown to
produce an activation of glycogen phosphorylase activity which is significantly
greater in hearts derived from alloxan-diabetic and spontaneously diabetic BB/W
animals than from normal animals (61 63, 64). While the catecholamine- induced
activation of cardiac phosphorylase has been shown to result from an increase in
phosphorylase kinase activity, cAMP levels and protein kinase activity in
response to epinephrine in diabetic hearts were shown not to be significantly
different than the normal in response to the hormone (1 64). While the majority of
epinephrine s stimulatory effects are thought to be mediated through the
activation of ~-adrenergic receptors (25,78), recent reports have indicated that
the actual number of surface ~-adrenergic receptors in the diabetic rat heart
decreases without altering the affinity of the receptor for the agonist (44 48,78).
Since the hypersensitive response of diabetic glycogen phosphorylase to
catecholamine stimulation does not appear to result from a simple change in
receptor number or agonist affinity, and since epinephrine is capable of eliciting
both a- and ~-adrenergic responses in the heart, a potential role for a-adrenergic
mediation of the hypersensitivity effect exists.
The purpose of the following study was to determine whether the
hypersensitivity of glycogen phosphorylase activation by catecholamines in
alloxan-diabetic hearts is mediated by an a- or ~-adrenergic response. The
following work demonstrates that the hypersensitive response to epinephrine
stimulation in diabetic hearts occurs independently of a-adrenergic receptor
activation and is mediated solely by the ~-adrenergic receptor system.
B. Results.
Earlier studies carried out in this laboratory showed that cardiomyocytes
in this primary culture system maintain their classic cardiac features such as
longitudinal striations of fiber bundles and cross striations of the various bands
(89). Plating of cardiomyocytes onto laminin-coated plastic culture dishes
resulted in preparations with greater than 90% rod shaped, viable cells.
The data presented in Figure 3 illustrate the dose dependent relationship
for epinephrine-stimulated activation of glycogen phosphorylase in
cardiomyocytes from normal and alloxan-diabetic rats, 3 and 24 hours after
isolation. Both normal and alloxan-diabetic 3 hour cells were sensitive to the
effects of epinephrine over the concentration range of 1 x 10-7 M to 5.5 x 10-6 M
and exhibited identical kinetic responses (data not shown). For normal myocytes,
the half maximal response for phosphorylase activation occurred with 5.5 x 10-
M.: 1.25 epinephrine whereas those from alloxan-diabetic rats were significantly
(p .: 0.005) more sensitive to epinephrine stimulation since the half maximal
response was elicited with 2.4 x 10-7 M.: 1.05 epinephrine. After 3 hours in
primary culture, the maximal response elicited to epinephrine challenge was 12%
and 24% phosphorylase a. for normal and alloxan-diabetic myocytes,
respectively. Upon maintenance of these cells in culture for 24 hours prior to
hormonal challenge, the effective epinephrine concentration range to which 24
hour myocytes were responsive underwent a significant (p .: 0.005) leftward shift
relative to those maintained in culture for 3 hours. After 24 hours, the half
maximal concentration of epinephrine required for phosphorylase activation in
myocytes from diabetic animals was an order of magnitude lower (EC50 = 4. 1 x
10-8 M.: 1. 10). In the normal , 24 hdur cardiomyocytes, there was an in vitro
induction of the hypersensitive response since the half maximal response was
elicited with 4.4 x 10-8 M.: 1.17 epinephrine and is comparable to the diabetic
myocyte, 24 hour response. After 24 hours in culture, the maximal response
which was elicited to epinephrine stimulation was approximately 50%
phosphorylase .a for both normal and alloxan-diabetic derived cardiomyocytes.
Similar dose response relationships were established for 3 and 24 hour, normal
and alloxan-diabetic rat cardiomyocytes in response to stimulation with the ~-
agonist isoproterenol (data not shown). The mechanism by which this in vitro
hypersensitivity response is induced in normal cells and is further enhanced in
diabetic cells in culture is unknown.
To determine if the hypersensitive response of phosphorylase to
catecholamine stimulation was potentially mediated by an a-adrenergic effect,
normal and diabetic cardiomyocytes were preincubated with propranolol , a ~-
adrenergic receptor antagonist, prior to challenge with phenylephrine, a selective
a1 receptor agonist. Figure 4 clearly demonstrates that direct alpha adrenergic
stimulation of normal and diabetic cardiomyocytes results in only minimal
activation of phosphorylase. Unlike with epinephrine stimulation , there is 
hypersensitive phosphorylase response elicited upon phenylephrine challenge.
To further address the potential role for alpha adrenergic mediation of the
hypersensitive phosphorylase response to epinephrine, both normal and alloxan-
diabetic cardiomyocytes were incubated with either prazosin , a selective 
receptor antagonist , or propranolol, a 
~1 /~2 receptor antagonist, for 1 hour prior
to epinephrine challenge. As illustrated in Figures Sand 6, phosphorylase
activation was completely inhibited when either normal or diabetic, 3 or 24 hour
cells, were pretreated with propranolol. When 24 hour cardiomyocytes from
alloxan-diabetic or normal hearts were preincubated with prazosin, epinephrine-
stimulated activation of phosphorylase was attenuated by only 10%. There does
not appear to be any involvement of muscarinic receptors in the hypersensitive
response exhibited by the cells from alloxan-diabetic animals since the addition
of 0. 1 JlM atropine to cultured normal and diabetic cardiomyocytes failed to
prevent the hypersensitive phosphorylase response (data not shown). The
hypersensitive response of phosphorylase is also independent of insulin or
triiodothyronine (T3) treatment. When normal and diabetic cardiomyocytes were
cultured for 24 hours in the absence or presence of insulin (0. 1 JlM), T3 (75 JlM)
or insulin with T3, the response of phosphorylase to epinephrine stimulation was
unaltered (data not shown). In addition , induction of the hypersensitive response
of phosphorylase to epinephrine stimulation also occurred independently of the
presence of serum, BSA, palmitate and both eicosapentaenoic and
docasahexaenoic acid, two fatty acids whose levels are known to be increased in
the diabetic state (50,85). When applied exogenously to the culture medium
. these agents were unsuccessful in attenuating the hypersensitive response of
phosphorylase (data not shown). The hypersensitive response of glycogen
phosphorylase to catecholamine stimulation also occurred independently of
protein synthesis. When normal and alloxan-diabetic cardiomyocytes were
cultured for 3 hours, Figure , or 24 hours, Figure 8, with 1 or 10 JlM
cycloheximide , the phosphorylase response to epinephrine challenge was
unaltered. Incubation of primary cultured cardiomyocytes with cycloheximide was
shown to decrease protein synthesis by approximately one-third in normal
myocytes and one- half in diabetic cardiomyocytes as shown in Table 1. To what
extent these agents may act in concert with other factors to abolish the response
to adrenergic agonists is not known.
As depicted in earlier figures, diabetic cardiomyocytes exhibit an increased
sensitivity to epinephrine after 3 hours in culture which was further enhanced
after 24 hours. In normal cardiomyocytes, the hypersensitive activation of
phosphorylase by epinephrine was acquired upon culturing the cells for 24 hours.
These data suggest that the hypersensitive response of glycogen phosphorylase
activation , which is present in myocytes derived from alloxan-diabetic rats and is
acquired in vitro by normal rat cardiomyocytes, is mediated solely by the ~-
adrenergic receptor pathway.
c. Discussion.
The present study shows that epinephrine- induced activation of glycogen
phosphorylase in normal and alloxan-diabetic rat cardiomyocytes appears to be
mediated solely through ~-adrenergic receptor activation. When propranolol , a ~-
adrenergic receptor antagonist, was added to the cultured myocytes to inhibit this
component of epinephrine s action , the observed hypersensitivity effect was
abolished. Both prazosin and atropine failed to prevent the hypersensitive
activation of phosphorylase as did cycloheximide , insulin and/or T3. Isoproterenol
was found to have effects similar to epinephrine . in promoting phosphorylase
activation whereas phenylephrine had limited ability to activate the enzyme.
While earlier studies did suggest a potential role for (X1 adrenergic mediation of
the hypersensitivity effect, the data presented in this report fails to support this
hypothesis.
Since phosphorylase activity in both normal and alloxan-diabetic cells
cultured for 3 or 24 hours is only minimally activated in response to direct (X1
stimulation with phenylephrine, a major role for (X 1 mediation of the
hypersensitivity effect is doubtful. In addition, prazosin , a selective (X1 receptor
antagonist, had only limited success in blocking phosphorylase activation in all
cell preparations which is in agreement with other published studies (17). The
discrepancy between this work and earlier studies probably lies in the fact that
the initial studies utilized the perfused heart system in which receptor blockade is
dependent at least in part, on perfusion efficacy. Also, lower concentrations of
propranolol were used which may have been insufficient for complete ~-blockade
(64).
The possibility that the phosphorylase hypersensitivity effect may result as
an isolation or primary culture artifact seems unlikely since the effect has been
well documented utilizing other diabetic tissue preparations including the gravity
flow perfused heart (64) and the isolated working heart (63). Since the
hypersensitive response of phosphorylase is seen shortly after the isolation of
diabetic cardiomyocytes (within 3 hours) and is absent initially in normal
myocytes, the effect appears to be intrinsic to the diabetic state since both
normal and diabetic cells are isolated and maintained in an identical fashion. It is
only upon culturing of normal cardiomyocytes for 24 hours that the
hypersensitivity of phosphorylase activation is acquired in vitro and is further
enhanced in diabetic cardiomyocytes. The hypersensitive response of
phosphorylase to epinephrine-stimulation does not appear to result from a
change in the rate of protein synthesis as a consequence of placement into
primary culture. When normal and diabetic-derived cardiomyocytes were
maintained in culture for periods up to 72 hours, total protein synthesis as well as
phosphorylase synthesis were unaffected by diabetes (77).
Catecholamines have been shown to alter calcium flux (63), and
phosphorylase kinase, the enzyme responsible for converting phosphorylase to
its active form , is subject to regulation , in part, by calcium (19). Several reports
have documented abnormal calcium-metabolism in diabetic animals which , in
turn , could result in the alteration of calcium-dependent cardiac metabolism or
other calcium-sensitive systems (1 36, 43, 67). While the precise
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mechanism for the hypersensitivity of phosphorylase activation in the diabetic
heart, and the acquisition of this effect in cultured normal rat cardiomyocytes , is
unknown , one likely possibility is that it may result from modified calcium
homeostasis upon culturing of these cells. Changes in sarcoplasmic reticular
calcium transport (31), pump function (43), or calcium channel flux (67) in the
diabetic state have been documented and could all , individually, or 
combination , act to increase intracellular calcium levels to a point at which
glycogen phosphorylase kinase would respond in a hypersensitized fashion.
Another mechanism which might mediate the hypersensitivity of phosphorylase
activation is through altered signal transduction via the ~-adrenergic receptor.
Changes in receptor coupling or G protein interactions such as a decrease in Gi
or an increase in Gs activity would elicit the respective changes in adenylyl
cyclase activity which would be reflected in the activation of phosphorylase (73).
Since isolated rat cardiomyocytes contain primarily CX1 and ~1 receptors
with no CX2 and few ~2 receptors present at the myocyte surface, an alternate
means by which glycogen phosphorylase activation might be sensitized to
epinephrine stimulation could result from an up-regulation of ~1-receptors at the
cell surface during the time in which the cells are maintained in culture
(3, 87). This hypothesis seems unlikely since ~-receptor density has been
shown not to be significantly changed when isolated ratcardiomyocytes are
maintained in culture for periods up to 10 days (57).
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Figure 3. Dose response relationship for epinephrine-stimulated
phosphorylase activation in normal and alloxan-diabetic cardiomyocytes
after 3 and 24 hours in culture. Cardiomyocytes from normal and alloxan-
diabetic animals were equilibrated in supplemented minimal essential media
(MEM). Three hour normal (open circles) and diabetic cells (closed circles) were
challenged with epinephrine for 10 minutes on the same day on which they were
isolated whereas 24 hour normal (open squares) and diabetic (closed squares)
cells were maintained in culture overnight prior to hormonal challenge. Cultured
cells were assayed for phosphorylase activity. Plotted values are means .: S. E.M.
where n=6.
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Figure 4. Dose response relationship for phenylephrine-stimulated
phosphorylase activation in normal and alloxan-diabetic cardiomyocytes
after 3 and 24 hours in culture. Cardiomyocytes from normal and alloxan-
diabetic animals were isolated and equilbrated in supplemented MEM containing
10 11M propranolol for 1 hour prior to phenylephrine challenge. Three hour normal
(open circles) and diabetic (closed circles) cells underwent agonist challenge for
10 minutes on the same day on which they were isolated while 24 hour normal
(open squares) and diabetic cells (closed squares) were maintained in culture
overnight prior to antagonist addition. Frozen myocytes were assayed for
phosphorylase activity. Plotted values are means.: S. M. where n=
5 uM Epl
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Figure 5. Effect of adrenergic antagonists on epinephrine-stimulated
activation of phosphorylase in normal and alloxan-diabetic cardiomyocytes
after 3 hours in culture. Cardiomyocytes from normal (open bars) and alloxan-
diabetic animals (closed bars) were isolated and maintained in culture for 2 hours
prior to equilibration with supplemented MEM containing either 10 JlM propranolol
or 1 JlM prazosin for 1 hour. Three hour cardiomyocytes were then challenged
with 5. 5 JlM epinephrine for 10 minutes and assayed for phosphorylase activity.
Plotted values represent the mean j: S. M. where n=
5uM Epl
- + + - + - 
Control 10uM Propranolol 1uM Prazosln
Figure 6. Effect of adrenergic antagonists on epinephrine-stimulated
phosphorylase activation in normal and alloxan-diabetic cardiomyocytes
after 24 hours in culture. Cardiomyocytes from normal (open bars) and alloxan-
diabetic animals (closed bars) were isolated and maintained in culture overnight
in the absence of antagonist. The cells were then equilibrated in supplemented
MEM containing either 1 0 M propranolol or M prazosin for 1 hour prior to
agonist exposure. Myocytes were then challenged with 5. M epinephrine for 10
minutes and assayed for phosphorylase activity. Plotted values express the
mean .r S. M. where n=4.
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Figure 7. Effect of protein synthesis inhibition by cycloheximide on
epinephrine-stimulated phosphorylase activation in normal and alloxan-
diabetic cardiomyocytes after 3 hours in primary culture. Cardiomyocytes
from normal and alloxan-diabetic animals were equilibrated in supplemented
MEM with or without 1 or 10 11M cycloheximide. Three hour normal (open bars)
and diabetic myocytes (hatched bars) were challenged with 5.5 11M epinephrine
for 10 minutes and were subsequently assayed for phosphorylase activity.
Plotted values are means j: S. E.M. where n = 6.
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Figure 8. Effect of protein synthesis inhibition by cycloheximide on
epinephrine-stimulated phosphorylase activation in normal and alloxan-
diabetic cardiomyocytes after 24 hours in culture. Cardiomyocytes from
normal and alloxan-diabetic animals were equilbrated in supplemented minimal
essential medium with or without 1 or 10 11M cycloheximide. Twenty four normal
(open bars) and diabetic myocytes (hatched bars) were challenged with 5.5 11M
epinephrine for 10 minutes and were subsequently assayed for phosphorylase
activity. Plotted values are means.: S. M. where n = 6.
Table 1
Effect of cycloheximide on (35S)methionine incorporation in normal and alloxan-
diabetic cultured cardiomyocytes
Normal Diabetic
(% control) (% control)
Nontreated Myocytes 100 100
10JlM Cycloheximide 68.0 :t 6. 55.8 :t 4.4
fJlM Cycloheximide 62.2 :t 8. 55.3 :t 5.
Isolated cardiomyocytes were cultured for 2 hours in medium containing
(35S)methionine protein labeling mix (50 IlCilml) with or without cycloheximide.
(35S)methionine incorporation into acid precipitable protein was quantified after
incubating the myocytes with the labeled amino acid. The data shown are the
mean .: S. E.M. where n = 4.
CHAPTER IV
Effect of Fatty Acid Metabolites on Phosphorylase Activation
A. Introduction.
The onset of diabetes dramatically alters myocardial energy metabolism.
In the heart, plasma free fatty acids are the principal substrate from which the
myocardium derives its energy. In normal hearts, approximately 60% of the total
energy for metabolism is supplied by the oxidation of fatty acids, while glycolysis
provides approximately 30% (52). In the diabetic heart, the oxidation of fatty
acids may account for greater than 90% of the total energy produced (52).
In fatty acid metabolism , carnitine plays an essential role by enabling long
chain fatty acid moieties to be shuttled across the inner mitochondrial membrane
into the mitochondrial matrix where ~-oxidation occurs (Figure 9) (6, 75). The
fatty acids are first activated upon thioester linkage between the carbonyl group
of the fatty acid and the sulfhydryl group of coenzyme A (CoA) to form acyl CoA.
The acyl group is then transferred from the sulfur atom of CoA to carnitine via
carnitine palmitoyltransferase 1 (CPT-1) to form acylcarnitine and regenerate free
CoA. Newly formed acylcarnitine is transferred across the membrane by a
translocase. The acyl group is then transferred back to CoA on the matrix side of
the membrane via CPT-2. Free carnitine is then returned to the cytosolic side of
the membrane by the translocase in exchange for the incoming acylcarnitine.
It has been shown in diabetic hearts that accompanying the increased
utilization of fatty acids is a significant increase in the metabolites which are
! :
associated with fatty acid metabolism (29,52). The accumulation of fatty acid
metabolites is known to have adverse effects on the heart since these
compounds have been shown to affect critical enzyme systems (55), to alter
membrane integrity (35,75), and to affect certain signal transduction pathways
(49). The focus of the present study was to assess the potential effects of fatty
acid metabolites on glycogen phosphorylase activation in normal and acute,
alloxan-diabetic, primary culture cardiomyocytes. These studies demonstrate that
the hypersensitive response of phosphorylase to epinephrine in normal and acute
diabetic myocytes occurs independently of the presence of various fatty acid
metabolites.
B. Results.
The rationale behind this series of experiments was that upon the addition
of acylcarnitine, in this case palmitoylcarnitine, to cultured normal and alloxan-
diabetic cardiomyocytes, one would expect to see a potentiated phosphorylase
activation response to epinephrine if the presence of acylcarnitine was affecting
the enzyme. Similarly, if carnitine was rate limiting for acylcarnitine transport into
the matrix , after supplementation of the cultures with exogenous carnitine, one
would expect to see an attenuated phosphorylase activation response. The data
presented in Figures 10 A and 10 B ilustrate the effect of palmitoylcarnitine and
carnitine on epinephrine-stimulated phosphorylase activation in normal (Figure
10 A) and acute, alloxan- diabetic cardiomyocytes (Figure 10 B) after 3 hours in
primary culture. Supplementation of the culture medium with either 10 11M
palmitoylcarnitine or 1 mM carnitine failed to alter the phosphorylase activation
response to epinephrine in both normal and alloxan-diabetic derived
cardiomyocytes. The response of alloxan-diabetic myocytes with or without
palmitoylcarnitine or carnitine , was hypersensitive with respect to the normal
myocyte response and is reflected by the change in percent phosphorylase .a
(approximately 21 % and 13% phosphorylase .a for diabetic and normal myocytes,
respectively). When normal and alloxan-diabetic myocytes were maintained in
primary culture for 24 hours in the absence or presence of 10 Jl M
palmitoylcarnitine or 1 mM carnitine, the phosphorylase activation response to
epinephrine stimulation was largely unaffected. As shown in Figure 11 A for
normal and Figure 11 B for alloxan-diabetic cardiomyocytes, the addition of
palmitoylcarnitine or carnitine to myocyte cultures had a statistically insignificant
effect on decreasing the magnitude of the phosphorylase response 
epinephrine challenge. After 24 hours in culture, the phosphorylase response to
epinephrine stimulation in both normal and alloxan-diabetic myocytes, with or
without palmitoylcarnitine or carnitine, was approximately 30% phosphorylase 
.a.
Previous reports have demonstrated that the administration of insulin to
chronically diabetic rats could prevent or reverse altered myocardial function in
the diabetic heart (86). The next series of experiments was undertaken to
determine if fatty acid metabolism in diabetic myocytes could be stimulated upon
the addition of insulin. For these studies, normal and alloxan-diabetic myocytes
were cultured for 1 additional hour in the absence or presence of 1 mM carnitine
100 nM insulin or with carnitine and insulin. As shown in Figure 12 Afar normal
and Figure 12 B for alloxan-diabetic cardiomyocytes, the addition of carnitine,
insulin or the combination of these two agents, was not effective in altering the
response of phosphorylase to epinephrine stimulation. A similar trend was
observed for normal (Figure 13 A) and diabetic myocytes (Figure 13 B) after
maintaining the cells for 24 hours in the absence or presence of carnitine, insulin
or carnitine with insulin prior to challenge with epinephrine.
Lastly, to determine if carnitine palmitoyltransferase 1 (CPT- 1) activity was
affected in these cells, normal and alloxan-diabetic cardiomyocytes were
maintained in culture in the absence or presence of etomoxir. Etomoxir
irreversibly inhibits palmitoylcarnitine transferase activity with the net result being
the accumulation of long chain acyl CoA's within the cell (53,56). The actual
inhibitor is not etomoxir but the corresponding CoA ester which is formed in vivo
(51). Preincubation of normal (Figure 14 A) and alloxan-diabetic cardiomyocytes
(Figure 14 B) without or with etomoxir concentrations ranging from 1 nM to 10
JlM , did not affect the phosphorylase activation response to epinephrine after the
cells were maintained in culture for 3 hours. Maintenance of normal (Figure 
A) and alloxan-diabetic cardiomyocytes (Figure 15 B) in the absence or
presence of etomoxir for 24 hours also failed to alter epinephrine-stimulated
phosphorylase activation. Collectively, these data fail to support a crucial role for
fatty acid metabolite involvement in the activation of glycogen phosphorylase in
normal and acute, alloxan-diabetic cultured cardiomyocytes.
C. Discussion.
The present study demonstrates that the presence of endogenous fatty
acid metabolites does not affect phosphorylase activation in normal- and acute,
alloxan-diabetic-derived cardia myocyte cultures. When carnitine or
palmitoylcarnitine was added to 3 and 24 hour normal and alloxan-diabetic
cardiomyocytes, the subsequent activation of phosphorylase by epinephrine was
largely unaffected. The addition of exogenous carnitine in both the absence and
presence of insulin was also unsuccessful in attenuating the phosphorylase
response. Similarly, inhibition of carnitine palmitoyltransferase 1 activity by
etomoxir was shown not to affect phosphorylase activation in normal and diabetic
myocyte cultures. While the activity of several key enzymes including Ca+2-
Mg+2_A TPase (52) and signal transduction via arachidonic acid and leukotriene
cascades (49) are affected by the accumulation of long chain acylcarnitines and
acyl CoA' in the diabetic heart, these studies indicate that glycogen
phosphorylase activity is not affected by the presence of these compounds in
cardiomyocytes isolated from normal and acute (5 day), alloxan-diabetic animals.
To what extent phosphorylase activity is affected by the presence of these agents
in chronic diabetic animals is unknown.
Earlier studies have indicated that chronic administration of L-carnitine to
diabetic rats had a protective effect against the myocardial damage which is
associated with the onset of diabetes (75,76). While the precise mechanism for
the improvement in cardiac function in these animals is not known , the protective
effect was shown to be dependent on the duration of carnitine treatment and the
concentration of carnitine administered (75). While the present studies
investigated the effects of high dose carnitine treatment on phosphorylase
activation , maintenance of myocytes in culture for periods up to 48 hours in the
presence of carnitine was shown not to affect phosphorylase activation (data not
shown). While carnitine supplementation may exert beneficial effects in the
hearts from chronically diabetic rats, a major role for carnitine involvement in
phosphorylase activation in primary culture, acute, diabetic cardiomyocytes
seems unlikely.
The lack of an effect by insulin with or without carnitine on phosphorylase
activation was not suprising. It had been shown that when cultures of normal and
alloxan-diabetic cardiomyocytes were supplemented with insulin prior to
epinephrine stimulation, the subsequent activation of phosphorylase was
unaffected (11). Although other studies did suggest that insulin treatment could
prevent some of the more adverse cardiac effects which are associated with
chronic diabetes, insulin therapy was shown to be effective only when insulin
treatment was initiated with the onset of disease (86). Since both insulin and
carnitine were added to ventricular myocyte cultures several hours after the cells
were placed into primary culture, it seems quite likely that these agents elicit their
protective effects on the heart in vivo but not in vitro.
In isolated working hearts, inhibition of carnitine palmitoyltransferase 1
activity by etomoxir was shown to significantly improve myocardial function in
acute and chronic diabetic, ischemic hearts (54 56). This effect was shown to be
concentration dependent (54 56). When lower (nanomolar) concentrations of
etomoxir were infused into the diabetic hearts, there was a marked decrease in
long chain acylcarnitine levels with little or no effect on cardiac function
(53, 54,56). At higher (micromolar) concentrations of etomoxir, myocardial
function improved significantly, however, improved function was not correlated
with a decrease in long chain acylcarnitines and acyl CoA's (53, 56). The lack
of reduction of the acyl compounds at high etomoxir concentrations in all
probabilty resulted from the inhibition of not only CPT- 1 but CPT-2 as well
(Figure 9) (54 56). In the present study, the effects of high and low etomoxir
concentrations on phosphorylase activation in normal and alloxan-diabetic
myocyte cultures was assessed. The data suggest that etomoxir does not alter
phosphorylase activation under these conditions. Collectively, these studies
demonstrate that the presence of fatty acid metabolites does not affect
phosphorylase activation by epinephrine in normal and acute alloxan-diabetic-
derived ventricular myocyte cultures.
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Figure 9. Overview of fatty acid metabolism.
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Figure 10 A. Effect of palmitoylcarnitine and carnitine on epinephrine-
stimulated phosphorylase activation in normal cardiomyocytes after 3
hours in culture. Cardiomyocytes from normal animals were isolated and
maintained in culture for 2 hours prior to equilibration in supplemented MEM
without (closed bars) or with 10 IlM palmitoylcarnitine (hatched bars) or 1 mM
carnitine (open bars) for 1 hour. Three hour cells were then challenged with 5.
IlM epinephrine for 10 minutes and assayed for phosphorylase activity. Plotted
values represent the mean I. S. E.M. where n = 6.
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Figure 10 B. Effect of palmitoylcarnitine and carnitine on epinephrine-
stimulated phosphorylase activation in alloxan-diabetic cardiomyocytes
after 3 hours in culture. Cardiomyocytes from diabetic animals were isolated
and maintained in culture for 2 hours prior to equilibration in supplemented MEM
without (closed bars) or with 10 IlM palmitoylcarnitine (hatched bars) or 1 mM
carnitine (open bars) for 1 hour. Three hour cells were then challenged with 5.
IlM epinephrine for 10 minutes and assayed for phosphorylase activity. Plotted
values represent the mean I S.E.M. where n = 6.
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Figure 11 A. Effect of palmitoylcarnitine and carnitine on epinephrine-
stimulated phosphorylase activation in normal cardiomyocytes after 24
hours in culture. Cardiomyocytes from normal animals were isolated and
maintained in culture for 24 hours in the absence (closed bars) or presence of
either 10 11M palmitoylcarnitine (hatched bars) or 1 mM carnitine (open bars).
Cells were challenged with 5.5 11M epinephrine for 10 minutes and were assayed
for phosphorylase activity. Plotted values represent the mean.: S. E.M. where n =
Exposure Time to 5.5uM Epinephrine (minutes)
Figure 11 B. Effect of palmitoylcarnitine and carnitine on epinephrine-
stimulated phosphorylase activation in alloxan-diabetic cardiomyocytes
after 24 hours in culture. Cardiomyocytes from diabetic animals were isolated
and maintained in culture for 24 hours in the absence (closed bars) or presence
of either 10 11M palmitoylcarnitine (hatched bars) or 1 mM carnitine (open bars).
Cells were challenged with 5.5 11M epinephrine for 10 minutes and were assayed
for phosphorylase activity. Plotted values represent the mean.: S. M. where n =
Exposure time to 5.5uM epinephrine .(mlnutes)
Figure 12 A. Effect of carnitine and insulin on epinephrine-stimulated
phosphorylase activation in normal cardiomyocytes after 3 hours 
culture. Myocytes from normal animals were isolated and maintained in primary
culture for 2 hours prior to equilbration with media without (closed bars) or with 
mM carnitine (open bars), 100 nM insulin (hatched bars) or both carnitine and
insulin (speckled bars). Three hour myocytes were challenged for 10 minutes
with 5. 5 JlM epinephrine and assayed for phosphorylase activity. Plotted values
represent the mean:t S. E.M. where n = 6.
Exposure Time to 5.5uM Epinephrine (minutes)
Figure 12 B. Effect of carnitine and insulin on epinephrine-stimulated
phosphorylase activation alloxan-diabetic cardiomyocytes after 3 hours in
culture. Myocytes from diabetic animals were isolated and maintained in primary
culture for 2 hours prior to equilibration with media without (closed bars) or with 
mM carnitine (open bars), 100 nM insulin (hatched bars) or both carnitine and
insulin (speckled bars). Three hour myocytes were challenged for 10 minutes
with 5. 5 JlM epinephrine and assayed for phosphorylase activity. Plotted values
represent the mean.: S. E.M. where n = 6.
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Figure 13 A. Effect of carnitine and insulin on epinephrine-stimulated
phosphorylase activation in normal cardlomyocytes after 24 hours in
Exposure time to 5.5uM Epinephrine (minutes)
culture. Cardiomyocytes from normal animals were maintained in culture for 24
hours in the absence (closed bars) or presence of 1 mM carnitine (open bars),
100 nM insulin (hatched bars) or both carnitine and insulin (speckled bars). Cells
were challenged with 5. M epinephrine for 10 minutes and assayed for
phosphorylase activity. Plotted values represent the mean.: S. E.M. where n = 6.
Exposure time to 5.5uM epinephrine (minutes)
Figure 13 B. Effect of carnitine and insulin on epinephrine-stimulated
phosphorylase activation in alloxan-diabetic cardiomyocytes after 24 hours
in culture. Cardiomyocytes from diabetic animals were maintained in culture for
24 hours in the absence (closed bars) or presence of 1 mM carnitine (open bars),
100 nM insulin (hatched bars) or both carnitine and insulin (speckled bars). Cells
were challenged with 5.5 11M epinephrine for 10 minutes and assayed for
phosphorylase activity. Plotted values represent the mean:t S. E.M. where n = 6.
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Figure 14 A. Effect of etomoxir on epinephrine-stimulated phosphorylase
activation in normal cardiomyocytes after 3 hours in culture.
Cardiomyocytes from normal animals were maintained in primary culture for 2
hours prior to the addition of etomoxir. Cells were equilibrated for 1 additional
hour prior to challenge with 5.5 IlM epinephrine for 10 minutes. The myocytes
were assayed for phosphorylase activity. Plotted values represent the mean j:
E.M. where n = 6.
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Figure 14 B. Effect of etomoxir on epinephrine-stimulated phosphorylase
activation in alloxan-diabetic cardiomyocytes after 3 hours in culture.
Cardiomyocytes from diabetic animals were maintained in primary culture for 2
hours prior to the addition of etomoxir. Cells were equilibrated for 1 additional
hour prior to challenge with 5.5 11M epinephrine for 10 minutes. The myocytes
were assayed for phosphorylase activity. Plotted values represent the mean .:
E.M. where n = 6.
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Figure 15 A. Effect of etomoxir on epinephrine-stimulated phosphorylase
activation in normal cardiomyocytes after 24 hours in culture. Cells from
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normal animals were maintained in culture for 24 hours in the absence (control)
or presence of etomoxir. Myocytes were challenged with 5.5 JlM epinephrine for
10 minutes and the cells were assayed for phosphorylase activity. Plotted values
represent the mean .: S. E.M. where n = 6.
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Figure 15 B. Effect of etomoxir on epinephrine-stimulated phosphorylase
activation in alloxan-diabetic cardiomyocytes after 24 hours in culture. Cells
from diabetic animals were maintained in culture for 24 hours in the absence
(control) or presence of etomoxir. Myocytes were challenged with 5.5 JlM
epinephrine for 10 minutes and the cells were assayed for phosphorylase activity.
Plotted values represent the mean.: S. E.M. where n = 6.
CHAPTER V
Potential for G-Protein Involvement in Phosphorylase Activation:
Evidence for a Post-Receptor Defect
A. Introduction.
Glycogen metabolism is acutely regulated by several hormones which
promote the synthesis of glycogen for storage or its degradation for use as a
cellular energy source (20,27). Glycogen phosphorylase, the enzyme directly
responsible for glycogen breakdown , is regulated in the heart by epinephrine, a
circulating catecholamine, which activates the enzyme via the ~-adrenergic
receptor system (7 11, 68). While the actual number of surface ~-receptors is
significantly decreased in the diabetic myocardium (48,66,78), it has been shown
that glycogen phosphorylase activity in isolated, alloxan-diabetic cardiomyocytes,
as well as in other diabetic heart preparations, responds to epinephrine
stimulation in a hypersensitive fashion (5, 63,64). Earlier studies carried out in
this laboratory have shown that cells derived from alloxan-diabetic animals
exhibit a hypersensitive glycogen phosphorylase re.sponse to epinephrine
challenge which was apparent 3 hours after cell isolation and was further
enhanced upon maintenance of these cells in primary culture for 24 hours
(11 89). Cells derived from normal animals initially lacked this response to
epinephrine after 3 hours in culture although maintenance of these cells in culture
for 24 hours resulted in an in vitro acquisition of the hypersensitive response (11).
While the response to catecholamine stimulation has been shown to be mediated
through the activation of surface ~-adrenergic receptors (11), the physiological
basis for the hypersensitive response is unknown.
Activation of glycogen phosphorylase by epinephrine requires the coupling
of surface ~-receptors to the adenylyl cyclase cascade system by receptor-linked
guanine nucleotide regulatory or G-proteins (4 15). For hormones such as
epinephrine which utilize cAMP as an intracellular messenger, two groups of G-
proteins, Gs and Gi , are known to mediate the receptor-dependent stimulation
and inhibition of adenylyl cyclase activity, respectively (34 81). ADP-ribosylation
of Gs by cholera toxin or Gi by pertussis toxin , directly affects the ability of these
proteins to couple efficiently to their receptor and effector systems (4 15). Any
alteration in the coupling between the appropriate G-protein and adenylyl
cyclase, which is responsible for intracellular cAMP production , could ultimately
influence the subsequent activation of glycog n phosphorylase.
The aim of this study was to determine if the hypersensitive response of
glycogen phosphorylase activation to catecholamine stimulation could result from
altered signal transduction through the ~-adrenergic receptor system or from a
post-receptor defect. The present work demonstrates that while Gs mediates the
hypersensitive activation of glycogen phosphorylase in response to epinephrine
stimulation , the hypersensitive response which is observed in alloxan-diabetic
cardiomyocytes and is induced in vitro in normal myocytes is due to a defect at a
post-receptor site.
B. Results.
To assess the potential for G-protein involvement in the hypersensitive
response of glycogen phosphorylase to catecholamine stimulation , the data
presented in Figure 16 illustrate the effect of cholera toxin on the epinephrine-
induced activation of glycogen phosphorylase for normal and alloxan-diabetic
cardiomyocytes maintained in primary culture for 3 hours. In cells not exposed to
cholera toxin , the alloxan-diabetic cells exhibited almost a two-fold greater
response than the normal cells to epinephrine as reflected by the increase in
phosphorylase .a (17.5% vs. 10;5% for alloxan-diabetic and normal myocytes,
respectively). When normal and alloxan-diabetic cells were incubated with 25
f.g/ml cholera toxin for 1 hour prior to epinephrine stimulation , both normal and
alloxan-diabetic cells exhibited a potentiated response to the hormone (30.4% vs.
18.3% phosphorylase a for alloxan..diabetic and normal cells respectively). It 
interesting to note that the response of phosphorylase was enhanced to the
same extent in both normal and alloxan-diabetic myocytes after 1 hour
pretreatment with cholera toxin. The phosphorylase a response for both normal
and alloxan-diabetic, cholera toxin treated myocytes was 174% of non-toxin
treated control cells. Incubation of both normal and alloxan-diabetic
cardiomyocytes with cholera toxin for periods up to 1 hour in the absence of
epinephrine stimulation failed to elicit a change in phosphorylase a (data not
shown). Maintenance of normal cardiomyocytes in the presence of 25 f.g/ml
cholera toxin for 24 hours failed to alter the in vitro induction of the hypersensitive
response of phosphorylase to epinephrine whereas diabetic derived
cardiomyocytes were not viable after incubation with cholera toxin for 24 hours
(data not shown).
To determine if an inhibitory G-protein , namely Gi , could be involved in the
activation of phosphorylase, both normal and alloxan-diabetic cardiomyocytes
were incubated with g/ml pertussis toxin for 1 hour prior to stimulation with
epinephrine. As shown in Figure , preincubation of the cells with pertussis
toxin did not affect the myocyte response to epinephrine challenge suggesting
that the inhibitory G-protein , Gi , was not involved in the activation of
phosphorylase. Collectively, these data implicate a direct role for a cholera toxin
sensitive G-protein , probably Gs , in the activation of glycogen phosphorylase in
response to catecholamine challenge in both normal and alloxan-diabetic
cardiomyocytes.
To determine if the hypersensitive response of glycogen phosphorylase to
hormonal stimulation resulted from altered signal transduction through the ~-
adrenergic receptor system or from a defect present at a post-receptor site,
normal and alloxan-diabetic cardiomyocytes were challenged with forskolin , a
cardioactive diterpene which directly stimulates the adenylyl cyclase catalytic
subunit activity independently of Gs (80). Figure 18 ilustrates the dose response
relationship for forskolin-stimulated activation of glycogen phosphorylase for both
normal and alloxan-diabetic cardiomyocytes maintained in primary culture for 3
hours. Both normal and alloxan-diabetic myocytes were sensitive to the effects of
forskolin over the concentration range of 1 x 10-7 M to 1 x 10-4 M(1 x 10-4 M
forskolin was the highest concentration assayed due to solubility constraints).
The response to forskolin in these cells was rapid and maximal within 5 minutes
of challenge (data not shown). For normal myocytes, after three hours in culture,
the EC50 for forskolin-stimulated phosphorylase activation was estimated to be
7 x 10-5 M forskolin whereas, alloxan-diabetic myocytes maintained in culture
for 3 hours were more sensitive to forskolin activation since the half maximal
response was elicited with 2.2 x 10-6 M forskolin. The maximal phosphorylase a
response for forskolin-stimulated enzyme activation for 3 hour, normal and
alloxan diabetic cardiomyocytes was 2-3 fold greater than enzymatic activation in
response to epinephrine challenge (11).
When cardiomyocytes were maintained in culture for 24 hours, the
phosphorylase response for normal and alloxan-diabetic myocytes to forskolin
was identical and is shown in Figure 19. The half maximal response for
phosphorylase activation was elicited with 2.6 x 10-6 M and 1.3 x 10-6 M
forskolin for normal and diabetic myocytes, respectively, which does not
represent a statistically significant difference. These data collectively suggest that
the hypersensitive response of glycogen phosphorylase to epinephrine challenge
results from a defect at a post-receptor site occurring after the activation of
adenylyl cyclase.
C. Discussion.
The present study implicates a direct role for Gs mediation of the
hypersensitive response of glycogen phosphorylase to epinephrine stimulation in
alloxan-diabetic cardiomyocytes as well as in normal myocytes. Pretreatment of
cardiomyocytes with pertussis toxin prior to epinephrine challenge failed to affect
phosphorylase activation whereas pretreatment with cholera toxin resulted in a
potentiated response. This data suggested that a cholera toxin-sensitive G-
protein, probably Gs, mediates the hypersensitive response of glycogen
phosphorylase to catecholamine stimulation in diabetic-derived cardiomyocytes.
The absence of an effect with pertussis toxin was not suprising since the
hypersensitive response of phosphorylase to catecholamine stimulation is
mediated by the activation of surface ~-adrenergic receptors (11). These results
are also consistent with the findings of Hazeki and Ui (40) in that cAMP
accumulation was shown not to be significantly different from control in short term
cardiomyocyte cultures treated with pertussis toxin. Since the response 
phosphorylase was potentiated by the same magnitude in both normal and
alloxan-diabetic cardiomyocytes treated with cholera toxin , it seems unlikely that
the primary defect in the hypersensitive response of glycogen phosphorylase in
the diabetic heart results from altered Gs function. While Gs may mediate the
activation of glycogen phosphorylase in response to epinephrine, the
hypersensitive response which is present in the alloxan-diabetic cells and is
induced in vitro in normal cardiomyocytes appears to result principally from a
defect at a post-receptor site which lies after the activation of adenylyl cyclase in
this signaling pathway.
When normal and alloxan-diabetic cardiomyocytes were challenged with
forskolin, which directly stimulates adenylyl cyclase catalytic activity (80), alloxan-
diabetic cells, cultured for 3 hours, exhibited a hypersensitive phosphorylase
activation response. Normal cardiomyocytes, at 3 hours, were initially less
sensitive to forskolin challenge than the alloxan-diabetic cells, however
maintenance of these cells in culture for 24 hours resulted in an in vitro induction
of the phosphorylase response to a similar magnitude as the diabetic myocytes.
When alloxan-diabetic cardiomyocytes were maintained in primary culture for 3
hours , the hypersensitive response to forskolin was due only to a decrease in
EC50 relative to the controls whereas, when the cells were stimulated with
epinephrine, the enhanced sensitivity of phosphorylase was manifested by both a
decrease in EC50 and a two-fold increase in the maximal phosphorylase a
response (11). In addition , at 24 hours, there was a smaller leftward shift in the
EC50 for forskolin-stimulated phosphorylase activation which was accompanied
by only a modest increase in maximal phosphorylase a response. While the
difference between epinephrine- and forskolin- induced activation of
phosphorylase may, in part, be attributed to inherent differences in their sites of
action (receptor-dependent vs. receptor- independent), published reports have
suggested that differences exist between the ability of forskolin and ~-adrenergic
amines to increase cAMP and activate cAMP-dependent protein kinase in the
perfused rat heart (26). While the compartmentalization of cAMP in the heart
could account for the differences observed for the hypersensitive response of
phosphorylase to epinephrine and forskolin stimulation , further studies are
required to resolve this complex issue.
Since the hypersensitivity of glycogen phosphorylase in the diabetic heart
does not appear to result from a direct increase in surface ~,.receptors
(48, 66,78, 87), modified G-protein mRNA levels (37 70), or altered signal
transduction via the ~-adrenergic receptor (44), one alternate mechanism which
could account for the hypersensitive response of phosphorylase is through the
alteration of cytosolic free calcium levels. Recent studies have shown that the
intracellular calcium concentration is greater in cardiomyocytes derived from
diabetic animals when compared to control animals based on fura-2 fluorescence
measurements (1). In addition , abnormal cardiac calcium-metabolism in the
diabetic state has been well documented with defects present at several key
regulatory points (43,59). Changes in calcium channel flux (67 88), and
sarcoplasmic reticular calcium transport in the diabetic state (31,43, 55), could
each individually, or in concert, serve to increase intracellular calcium to a point
at which calcium-dependent and calcium-sensitive systems, such 
phosphorylase kinase, would respond in a hypersensitive fashion. Conversely, if
altered calcium homeostasis is to be directly implicated in the hypersensitive
response, one might expect to see an altered phosphorylase activation response
following epinephrine challenge after diabetic heart preparations are exposed to
sub physiological extracellular calcium concentrations. Previous studies have
indicated that when hearts from alloxan-diabetic animals were perfused with one-
third of the normal perfusate calcium concentration , the hypersensitivity of
phosphorylase activation to epinephrine was pa'1ially reversed (63).
While the hypersensitivity of the glycogen phosphorylase activation
pathway in response to direct catecholamine challenge appears to be an intrinsic
property of the diabetic heart, and not an isolation artifact, the possibility exists
that calcium homeostasis may be altered upon maintenance of these cells in
primary culture. Intracellular free calcium levels may be initially higher in cells
derived from alloxan-diabetic animals which would explain the hypersensitive
phosphorylase response to epinephrine which is exhibited by these cells 3 hours
after isolation as well as in other diabetic heart preparations (61 63,64, 81).
Maintenance of alloxan-diabetic cells, as well as normal cardiomyocytes, in
primary culture for 24 hours could result in the alteration of calcium channel
function or the phosphorylation states of one or more of the proteins which are
directly involved in maintaining intracellular free calcium concentrations.
Increased intracellular calcium concentrations could also serve to promote
significant change in phosphorylase kinase activity which is subject to
regulation , in part, by calcium (41). Similarly, changes in the activities or
localization of the enzymes responsible for maintaining the phosphorylation state
of phosphorylase kinase, could promote the hypersensitive activation of
phosphorylase. While cAMP and cAMP-dependent protein kinase activity is not
significantly affected in the diabetic state based on studies in perfused hearts
(45,63) and in isolated myocytes (79), changes in phosphorylase kinase
phosphatase activity, the enzyme responsible for dephosphorylating and
inactivating phosphorylase. kinase, could be reflected as a change in activity at
the level of phosphorylase. Differences in the intracellular localization of
phosphorylase or phosphorylase kinase could also affect the kinetics and/or
magnitude of the observed response to epinephrine.
While the precise physiological basis for the hypersensitivity phenomenon
is unknown , an alteration in one or several of the cellular components which
regulate intracellular calcium levels and/or phosphorylase kinase activity may
promote the hypersensitive activation of glycogen phosphorylase in the diabetic
heart. Further investigation is warranted to determine the precise role of
phosphorylase kinase and calcium in this pathway and whether alterations in
their regulation are responsible for the diabetes-associated defect 
phosphorylase activation.
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Figure 16. Effect of cholera toxin on epinephrine-stimulated phosphorylase
activation in normal and alloxan-diabetic cardiomyocytes after 3 hours in
culture. Cardiomyocytes from normal (open bars) and alloxan-diabetic animals
(hatched bars) were maintained in culture for 2 hours prior to equilibration with
supplemented MEM with 0.2 mM palmitate, 0.24% albumin with or without 25
f.g/ml cholera toxin , for 1 hour. Cardiomyocytes , cultured for 3 hours, were then
challenged with 5.5 f.M epinephrine (+ Epi) for 10 minutes and assayed for
phosphorylase activity. Plotted values represent the mean ;tS.E.M. where n = 6
for normal and n = 8 for alloxan-diabetic cell preparations. * Po: 0. 005 V5. normal
+ epinephrine. t P 0: 0. 025 V5. normal + epinephrine.
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Figure 17. Effect of pertussis toxin on epinephrine-stimulated
phosphorylase activation in normal and alloxan-diabetic cardiomyocytes
after 3 hours in culture. Cardiomyocytes from normal (open bars) and alloxan-
diabetic animals (hatched bars) were isolated and maintained in culture for 2
hours prior to equilibration with supplemented MEM with 0.2 mM palmitate,
24% albumin with or without 1 f.g/ml pertussis toxin for 1 additional hour.
Cardiomyocytes, cultured for three hours, cells were then challenged with 5.5 f.M
epinephrine (+Epi) for 10 minutes and assayed for phosphorylase activity.
Plotted values represent the mean i S.E.M. where n = 6 for both normal and
alloxan-diabetic cell preparations. * P .c 0. 025 V5. normal + epinephrine
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Figure 18. Dose response relationship for forskolin-stimulated
phosphorylase activation in normal and alloxan-diabetic cardiomyocytes
after 3 hours in primary culture. Cardiomyocytes from normal and alloxan-
diabetic animals were prepared and equilibrated in MEM with 0.2 mM palmitate
and 0.24% albumin. Normal (open circles) and alloxan-diabetic cells (closed
circles) were stimulated with forskolin for 15 minutes. The myocytes were later
thawed on ice and assayed for phosphorylase activity. Plotted values represent
the mean .: S. E.M. where n = 6 for both normal and alloxan-diabetic cell
preparations.
Figure 19.
-10
Log Forskolin Concentration
Dose response relationship for forskolin-stimulated
phosphorylase activation in normal and alloxan-diabetic cardiomyocytes
after 24 hours in primary culture. Cardiomyocytes were prepared from normal
and alloxan-diabetic animals and were allowed to equilbrate for 24 hours in MEM
with 0.2 mM palmitate and 0.24% albumin. Normal (open squares) and alloxan-
diabetic cells (closed squares) were challenged with forskolin for 15 minutes. The
myocytes were later thawed on ice and assayed for phosphorylase activity.
Plotted values represent the mean .: S. E.M. where n = 6 for both normal and
alloxan-diabetic cell preparations.
CHAPTER VI
Assessment of Cardiac Phosphorylase Kinase Activity in Response
to Catecholamine Stimulation
A. Introduction.
Phosphorylase kinase plays a pivotal role in the physiological control of
the glycogenolytic cascade by catalyzing the conversion of phosphorylase .b to
the active a form (2,58). In the heart, phosphorylase kinase exists as a complex
enzyme consisting of (X 4'~4' Y4.84 subunits and is regulated by both cAMP and
calcium (18, 84). The y.subunit of phosphorylase kinase. contains the enzyme
catalytic site while the 8-subunit, which is identical to calmodulin , is the site of
calcium-dependent allosteric regulation (84). In the heart, both the (X . and ~-
subunits function in a regulatory capacity and are phosphorylated in response to
hormonal stimuli (41 58). An increase in cardiac phosphorylase kinase activity is
better correlated with the cAMP-dependent phosphorylation of both the (X - and 
subunits than with phosphorylation of either subunit alone (22 58,71).
Phosphorylase kinase activity is affected not only by the presence of
allosteric effectors and covalent modification but also by pH (41). In cardiac
muscle, as in skeletal muscle, phosphorylase kinase has very little activity at pH
8 or below and is termed "nonactivated" (Figure 1) (22 ). In contrast, at pH
, the nonactivated form of phosphorylase kinase can undergo as much as a
50-fold increase in activity (22 58). Nonactivated phosphorylase kinase can be
converted to an activated form which has 25- to 50-fold more activity at pH 6.
and two-fold greater activity at pH 8.2 upon phosphorylation or partial proteolysis
(22,58). Phosphorylase kinase activity data typically report the ratio of the
enzyme s activity at pH 6.8 to that at pH 8.2 although these values are often
subject to wide dispersion of the data (84). Recent reports have indicated that the
most reliable and reproducible index of phosphorylase kinase activity is to
measure the specific activity of the enzyme at pH 6.8 (2,84).
Previous studies have indicated that the hypersensitive response of
glycogen phosphorylase to catecholamine stimulation in the diabetic heart results
from a defect present at a post-receptor site which lies after the activation of
adenylyl cyclase in the cAMP second messenger pathway (10,60, 64). While
earlier studies had demonstrated that cAMP and cAMP-dependent protein kinase
activity were unaffected by diabetes (45, 79), this data implicated a potential
role for phosphorylase kinase mediation of the hypersensitive response of
phosphorylase to epinephrine challenge in the diabetic heart (64). When
phosphorylase kinase activity was measured in gravity-flow perfused hearts from
normal and acute alloxan-diabetic rats, phosphorylase kinase activity was shown
to be two-fold greater in hearts derived from acute diabetic animals than from
normal animals following perfusion with epinephrine (64).
The purpose of the present study was to measure cardiac phosphorylase
kinase activity initially in perfused hearts (to optimize the assay parameters) and
subsequently in isolated cardiomyocytes to assess the potential role of
phosphorylase kinase in the hypersensitive activation of glycogen phosphorylase
in the diabetic heart. The results demonstrate that although the present assay for
phosphorylase kinase activity is an accurate and reliable method for measuring
the amount of active phosphorylase kinase activity in the heart, the assay
conditions must be further optimized before this system can be applied for
measurement of phosphorylase kinase activity in primary culture cardiomyocytes.
B. Results.
For these studies, measurement of phosphorylase kinase activity is based
upon the determination of phosphorylase 
.b phosphorylation in vitro Therefore,
the integrity of the substrate must be assessed to ensure optimal assay
conditions. Partially denatured phosphorylase .b would be a poorer substrate for
phosphorylation by phosphorylase kinase which would be manifested as a
decrease in the enzyme s specific activity (84). The data presented in Table 2
ilustrate the comparison of phosphorylase .b sources for use as a substrate to
assay phosphorylase kinase activity.
In these studies, hearts from normal animals were perfused with buffer
with (+ Epi) or without 10 JlM epinephrine (- Epi) prior to freezing in liquid
nitrogen. Frozen hearts were powdered and a heart homogenate was prepared.
After microcentrifugation, the heart cytosolic extracts were assayed for
phosphorylase kinase activity using commercially available phosphorylase 
preparations or phosphorylase .b, purified to near homogeneity, which was
provided by Dr. James Dobson. Phosphorylase kinase activity was routinely
assayed in the absence of phosphorylase .b (to determine the endogenous
phosphorylase .b content of the samples) and in the presence of phosphorylase
J =
J=-
.b. The data are expressed as the difference in cpm between the two
experimental conditions.
As shown in Table 2, in the assays which used Sigma s phosphorylase.b
as a substrate, the buffer control , in the absence of phosphorylase 
.b, showed
minimal or background 32p incorporation whereas the buffer control , in the
presence of phosphorylase 
.b showed about an 8-fold increase in the amount of
incorporated label. The increase in cpm in the control samples probably
represents the activity of the various contaminants (i.e. phosphorylase a,
phosphorylase kinase , phosphatases etc. ) which are present in this
phosphorylase 
.b preparation. When the extracts from hearts perfused without
epinephrine were assayed for phosphorylase kinase activity in the absence of
phosphorylase 
.b, there was an increase in the amount of 32p incorporated over
that of the control , which probably reflects the presence of endogenous
phosphorylase 
.b present in the heart extract. The increase in 32p incorporation
could not be attributed to endogenous cAMP-dependent protein kinase activity
present in the extracts since all assays contained 2 Jl9 cAMP-dependent protein
kinase inhibitor protein (PKI) in the reaction mixture (16). When the same sample
was assayed, this time in the presence of phosphorylase 
.b, 32p incorporation
was increased. The difference in cpm between the heart extract without
epinephrine, assayed in both the absence and presence of phosphorylase 
.b,
represents the phosphorylase kinase activity which is present in the heart extract.
A similar phosphorylase kinase activity trend was observed for the extract from
hearts perfused with epinephrine and assayed with and without phosphorylase.b.
The phosphorylase kinase activity in the heart extract perfused with epinephrine
was approximately 30% greater than the activity of the extract without
epinephrine. The observed increase in phosphorylase kinase activity due to
epinephrine stimulation in this study is in good agreement with previous reports
which measured the pH 6.8/pH 8.2 activity ratios for phosphorylase kinase 
normal hearts perfused with epinephrine (64). When commercially available
phosphorylase kinase was assayed under the same conditions as a positive
control , significant amounts of 32p incorporation into phosphorylase .b was
observed (data not shown).
When phosphorylase b. provided by Dr. Dobson was used as a substrate
for the phosphorylase kinase assay, similar results were obtained. When purified
phosphorylase .b was assayed in this system , the assay background was
significantly lower than that obtained with the phosphorylase 12 from Sigma. This
probably reflects the fact that this preparation was essentially free of the
impurities which could influence the assay results. When phosphorylase b. from
Boehringer Mannheim was used as the assay substrate , enzymatic activation
was not observed. The lack of enzyme activation with the Boehringer substrate
probably resulted from the presence of EDTA in the lyophilzed preparation which
could act to inhibit phosphorylase kinase activity which is subject to regulation by
calcium. What these data suggest is that the present assay for phosphorylase
kinase activity is a reliable indicator ofthe amount of active phosphorylase kinase
activity which is present in the rat heart and that the source of phosphorylase 
must be carefully selected and maintained to ensure optimal assay results.
In order to determine if the hypersensitive response of phosphorylase to
epinephrine stimulation was due to a defect at the level of phosphorylase kinase,
cardiomyocytes from normal animals were prepared and maintained in primary
culture for 3 and 24 hours with and without epinephrine stimulation. The isolated
myocytes were assayed for phosphorylase kinase activity using the
phosphorylase .b provided by Dr. Dobson as an assay substrate. When the
myocyte suspensions were assayed for phosphorylase kinase activity, enzyme
activation was not observed (data not shown). Although the amount of protein
present in the assay system exceeded the limits necessary for detection , there
was an apparent inhibition of phosphorylase kinase activity which was probably
due to the presence of excess EDTA from the myocyte wash buffer which
remained on the culture dishes when the cells were harvested from the plates.
The conditions for this assay need to be further refined before this method for
assaying phosphorylase kinase activity can be used in conjunction with primary
culture cardiomyocytes.
C. Discussion.
The results from these studies indicate that the present method for
measuring phosphorylase kinase activity is a reliable indicator of the enzyme
activity in the heart although special emphasis must be placed on maintaining the
substrate s integrity. While the assay was able to measure phosphorylase kinase
activity in perfused hearts, refinements are necessary before this system can be
applied to primary culture cardiomyocytes.
In the present study, when phosphorylase kinase activity was measured in
extracts from normal hearts perfused with epinephrine, the enzyme s activity was
approximately 30% greater than the activity in extracts from hearts perfused
without epinephrine. These results are consistent with other reports which
describe phosphorylase kinase activity in perfused hearts in response to other
hormonal effectors including epinephrine (64), PGE1 (60), and isoproterenol (39).
While the present study did not assess phosphorylase kinase activity in the
diabetic heart, previous studies have suggested that phosphorylase kinase plays
a key role in the hypersensitive activation of phosphorylase to hormonal
stimulation in the diabetic heart (60,63,64).
Phosphorylase kinase has long been known to be activated by the
allosteric effects of calcium (24). Several studies have demonstrated that cardiac,
calcium-dependent metabolism is altered in the diabetic state with defects
present at multiple regulatory sites (31 43,67). Recent reports have demonstrated
that the intracellular calcium concentration is greater in diabetic cardiomyocytes
than in normal cardiomyocytes based on fura-2 measurements (1). Changes in
sarcoplasmic reticular calcium transport (31 43), and calcium pump and channel
function (43, 88), could increase intracellular calcium levels to a point at which
calcium-regulated enzymes, such as phosphorylase kinase, would respond with
increased sensitivity. In turn , this enhanced sensitivity would be manifested as a
change in activity at the level of phosphorylase.
The activation of phosphorylase kinase, either by an increase in calcium
concentrations or by cAMP-dependent phosphorylation , results solely as a
consequence of a change in the enzyme s Vmax without a change in affinity (Km)
for phosphorylase (65). The kinetic properties of phosphorylase kinase are such
that incremental changes in both calcium and cAMP lead to synergistic increases
in the amount of active phosphorylase (65). It becomes tempting to speculate on
the relevance of these observations with respect to the hypersensitive activation
of phosphorylase in the diabetic heart. Upon placement of ventricular
cardiomyocytes into primary culture, intracellular calcium concentrations would
1, '
be expected to be greater in diabetic-derived cardiomyocytes with respect to
normal myocytes. Following epinephrine stimulation, one would expect to see a
greater change in phosphorylase activation in the diabetic myocytes relative to
the normal myocytes due to the synergistic effects of both increased intracellular
calcium and cAMP acting at the level of phosphorylase kinase. Furthermore, as
the cells are maintained in primary culture for longer times (24 hours),
intracellular calcium concentrations in both normal and diabetic myocytes would
be expected to be in a state of change as a consequence of primary culture. It
follows that after maintaining these cells in culture for 24 hours, that both normal
and diabetic myocytes could exhibit an enhanced phosphorylase activation
response due to the increase in cAMP following epinephrine stimulation and even
greater intracellular calcium concentrations working in concert to influence
phosphorylase kinase and hence phosphorylase activation. Conclusive proof of
this hypothesis wil require more definitive study.
Table 2
Comparison of phosphorylase b. sources for use as a substrate to assay
phosphorylase kinase activity
Source Phos + Phos Difference
(cpm z SEM) (cpm z SEM)
Phosphorylase b. (Sigma)
Control 145 :t 7.4 1295:t 1150
- Epi 3294 :t 224 6815 :t 11 5 3521
+ Epi 2985 :t 1 86 7520 :t 420 4535
Phosphorylase Q (Dobson)
Control 1 00 :t 5. 365 :t 1 3 265
- Epi 3230 :t 130 6068:t 131 2838
+ Epi 2802 :t 246 6688 :t 219 3386
Phosphorylase Q (Boehringer Mannheim)
Control 87 :t 6. 540 :t 1 4 453
- Epi 2435 :t 18 31 37 :t 1 47 702
+ Epi 2892 :t 229 3614 :t 80 722
Normal hearts were perfused without (-Epi) or with 10 JlM epinephrine (+Epi)
prior to freezing in liquid nitrogen. Heart cytosolic extracts were prepared and
(32p) incorporation into phosphorylase 
.Q was measured in the presence of
9tein extract or homogenization buffer which served as the control. The data
are expressed as the mean.: S. E.M. where n = 3.
CHAPTER VII
Summary and General Discussion
The primary focus of these studies was to characterize the molecular
basis for the hypersensitive response of glycogen phosphorylase to
catecholamine stimulation in primary culture, diabetic, rat ventricular
cardiomyocytes. Toward this goal , several key regulatory aspects which could
promote the hypersensitive response of phosphorylase, were investigated.
Initial studies indicated that rat cardiomyocytes derived from alloxan-
diabetic animals exhibited a hypersensitive phosphorylase activation response to
epinephrine stimulation relative to cells obtained from normal animals, which was
apparent after 3 hours in primary culture and was further enhanced after
maintenance of the cells in culture for 24 hours. While normal myocytes did not
exhibit the hypersensitive response to epinephrine after 3 hours in culture, the
response was acquired by these cells in vitro after 24 hours in primary culture
(Figure 3). Based on studies utilzing selective (X- and ~-adrenergic receptor
agonists and antagonists, the hypersensitive response of glycogen
phosphorylase to epinephrine stimulation was shown to be mediated solely
through the activation of surface ~-adrenergic receptors.
To determine whether the presence of fatty acid metabolites could affect
catecholamine-stimulated phosphorylase activation , normal and acute, alloxan-
diabetic derived cardiomyocytes were maintained in culture for either 3 or 24
hours in the presence of various fatty acid metabolies (Chapter 4).
Palmitoylcarnitine, carnitine or carnitine in the presence of insulin failed to alter
phosphorylase activation in response to epinephrine. In addition, inhibition of
carnitine palmitoyltransferase 1 (CPT-1) activity by etomoxir did not alter the
enzyme s response to the hormone. Collectively, these data indicated that the
presence of fatty acid metabolites does not affect epinephrine-stimulated
phosphorylase activation in normal and acute, alloxan-diabetic derived
cardiomyocytes.
To address whether the hypersensitive response of phosphorylase
resulted from altered signal transduction through the ~-adrenergic receptor
system or from a post-receptor defect, normal and diabetic-derived
cardiomyocytes were incubated with either cholera or pertussis toxin prior to
hormonal stimulation. Pretreatment of both normal and diabetic myocytes with
cholera toxin resulted in a potentiated response to epinephrine stimulation
whereas pertussis toxin did not affect the activation of this signaling pathway
(Figures 16 & 17). Subsequent challenge of normal and diabetic myocytes with
forskolin exhibited a similar activation pattern to that obtained with epinephrine
(Figures 18 & 19). These studies demonstrated that while Gs does mediate the
hypersensitive activation of glycogen phosphorylase in response to epinephrine
stimulation , the hypersensitive response which is observed in alloxan-diabetic
myocytes and is acquired in vitro in normal myocytes principally results from a
defect occurring at a post-receptor site.
Lastly, to assess the role of phosphorylase kinase in the hypersensitive
activation of glycogen phosphorylase in the diabetic heart, phosphorylase kinase
activity was measured (Chapter 6). These studies indicated that while
measurement of the enzyme s specific activity at pH 6.8 is an accurate and
reliable method for determining the amount of active phosphorylase kinase
activity in the whole heart, the assay conditions need to be refined before this
method can be used for measuring phosphorylase kinase activity in primary
culture cardiomyocytes.
While the precise mechanism for the hypersensitive response of cardiac
phosphorylase in diabetic rats is stil unidentified, the data presented in this thesis
provides supporting evidence which localizes the phenomenon to a post-receptor
site which occurs during the later stages of the phosphorylase activation
cascade. Collectively, these studies demonstrate that the defect is not present at
the level of the ~-adrenergic receptor, the activation of the stimulatory G-protein
Gs, or the activation of adenylyl cyclase. Earlier studies have demonstrated that
cardiac cyclic AMP accumulation and the increase in cAMP-dependent protein
kinase activity ratio following ~-adrenergic stimulation are also unaffected by
diabetes (64,79). Similarly, phosphorylase phosphatase activity, the enzyme
which is responsible for dephosphorylating and inactivating phosphorylase a, was
shown to be unaltered by either epinephrine or diabetes (64). Based on this
information , it is reasonable to hypothesize that the hypersensitivity of glycogen
phosphorylase activation in primary culture diabetic ventricular cardiomyocytes is
due to an enhanced sensitivity of phosphorylase activation at the level of
phosphorylase kinase.
There are three plausible mechanisms which could account for the
enhanced activation of glycogen phosphorylase in the diabetic heart. First, if
there is a decrease in the phosphatase activities which regulate phosphorylase
kinase activity, the net result would be a sustained activation of the enzyme
which would be reflected by an enhanced activity response at the level of
phosphorylase. Phosphorylase kinase is subject to dephosphorylation by not only
protein phosphatase 1 but also by protein phosphatase 2A (21 23). While the
type 1 protein phosphatase accounts for the majority of phosphorylase kinase
activity (toward the ~-subunit which plays the dominant role in the enzyme
activation), protein phosphatase 2A is the major enzyme which acts on the 
subunit of phosphorylase kinase (21). How these enzymes function together 
vivo to bring about the inactivation of phosphorylase kinase is a complex issue
which has not been fully resolved. Therefore, it becomes difficult to speculate on
the specific effects of diabetes on phosphorylase kinase phosphatase activity in
the heart.
The second mechanism which could promote the hypersensitive activation
of phosphorylase could be the presence of an inhibitory factor (or factors) in vivo
which exists in the heart to suppress the enzyme ctivation in response to
hormonal stimuli. If this humoral mediator became altered with the onset of
diabetes, such that it was either missing or inactivated, the enhanced activation
of phosphorylase following epinephrine stimulation would be seen in whole
hearts or primary culture cardiomyocytes derived from diabetic animals. The
existence of a humoral factor which blunts phosphorylase activation in the heart
while possible is not probable due to the observation that upon supplementation
of 3 and 24 hour, normal cardiomyocyte cultures with serum (concentrations
ranging from 0 to 100%), the activation of phosphorylase was not altered in
response to epinephrine challenge (Chapter 3).
The third mechanism which could account for the hypersensitive activation
of phosphorylase may be due, in part, to the allosteric effects of calcium on
phosphorylase kinase activity. Several studies have documented abnormal
calcium metabolism in the diabetic heart with the net result being an increase in
intracellular free calcium (1 31, 43, 88). As described earlier, cardiac
phosphorylase kinase is regulated by cAMP-dependent protein kinase and the
allosteric effects of calcium (18,84). While a change in the phosphorylation state
of the enzyme , due to the action of the kinase, would be a stable, distinguishable
change, the allosteric effect of calcium on phosphorylase kinase is not a stable
change which cannot be easily detected or assayed (60).
One observation which is consistent with the role of calcium in the
hypersensitive activation of phosphorylase is the observation that when
cardiomyocytes are maintained in primary culture for 3 or 24 hours, basal
phosphorylase activity is identical for normal and diabetic-derived cells
(approximately 5% phosphorylase a). It is only when diabetic-derived or normal
myocytes after 24 hours in culture, are subject to ~-stimulation that they exhibit
the hypersensitive phosphorylase response. Since both calcium and cAMP
produce synergistic increases in the amount of active phosphorylase kinase
which is present in the heart, it seems highly probable that increased intracellular
free calcium is directly involved in promoting the hypersensitive activation of
phosphorylase by virtue of its actions at the level of phosphorylase kinase.
Further work will be required to provide evidence to support this
hypothesis. The implications that an abnormality in calcium metabolism is
involved in mediating the adverse pathological effects of diabetes remains to be
determined.
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